跳至主要内容
临床试验/NCT01288898
NCT01288898已完成1 期

A Double-blind, Placebo-controlled, Dose Escalating Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of ASP1941 and to Explore the Effect of ASP1941 on Urine and Blood Glucose Levels in Healthy Subjects

Astellas Pharma Inc1 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2007年5月最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
48
试验地点
1
主要终点
Safety and Tolerability assessed by the incidence of adverse events, vital signs, physical examinations, 12-lead ECG and lab-tests

研究概览

简要总结

This study determined the safety of ASP1941 after a single and multiple once-daily doses for 10 days in healthy subjects. In addition, the Pharmacokinetics (PK) and Pharmacodynamics (PD) of ASP1941 were assessed.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Basic Science
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Body weight between 60-100kg, body mass index (BMI) between 20-30 kg/m2, inclusive

排除标准

  • Fasting Plasma Glucose (FPG) > 6.4 mmol/l
  • HbA1c > 6.2%
  • Abnormal pulse of blood pressure at screening, as judged by the investigator

结局指标

主要结局

Safety and Tolerability assessed by the incidence of adverse events, vital signs, physical examinations, 12-lead ECG and lab-tests

时间窗: 31 days

次要结局

  • Pharmacokinetics assessed by the ASP1941 plasma concentration change(up to 96 hours after last dose)
  • Pharmacodynamics assessed by the ASP1941 glucose concentration changes in blood and urine(up to 96 hours after last dose)

研究者

申办方类型
Industry

研究点 (1)

Loading locations...

相似试验